v3.22.4
Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2021
Dec. 31, 2019
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Apr. 01, 2022
Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of common shares available for future issuance (in shares)     17,410,189   17,410,189   4,659,315 13,033,788
Common shares outstanding (in shares)     1,286,372   1,286,372     2,188,860
Intrinsic value of stock options exercised         $ 200      
Stock options exercised (in shares)         57,678 0    
Weighted average fair value at the grant date (in dollars per share)         $ 4.22      
Share based compensation expense     $ 8,856 $ 9,954 $ 24,462 $ 21,443    
Research and development expenses                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Share based compensation expense     4,137 4,797 11,556 8,602    
Stock Options                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Unrecognized equity-based compensation related to unvested stock options     $ 38,200   $ 38,200      
Remaining weighted average service period for recognition         2 years 8 months 15 days      
Restricted stock units                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Restricted stock units outstanding (in shares)     4,528,774   4,528,774     2,670,864
Unrecognized equity-based compensation related to RSUs     $ 20,700   $ 20,700      
Remaining weighted average service period for recognition         2 years 9 months 29 days      
Restricted stock units, grants in period (in shares)         2,473,469      
Roivant Sciences Ltd. (RSL)                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Share based compensation expense     0 100 $ 100 400    
Roivant Sciences Ltd. (RSL) | Restricted stock units                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Unrecognized equity-based compensation related to unvested stock options     100   100      
Share based compensation expense     $ 100 $ 100 $ 300 $ 500    
Restricted stock units, grants in period (in shares) 73,155              
Award vesting period 4 years              
2019 Equity Incentive Plan                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of common shares available for future issuance (in shares)   5,500,000 1,286,372   1,286,372      
Maximum number of shares issued (in shares)   16,500,000            
Percentage of common stock outstanding   4.00%            
Common shares outstanding (in shares)     8,355,667   8,355,667      
2019 Equity Incentive Plan | Restricted stock units                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Restricted stock units outstanding (in shares)     4,528,774   4,528,774      
2018 Equity Incentive Plan                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common shares outstanding (in shares)     2,921,615   2,921,615